Arhum: Evidence-Based Insights for Prenatal Wellness and Labor Support

Arhum is a U.S.-based prenatal health technology company founded in 2019 and headquartered in Portland, Oregon. It specializes in FDA-cleared, CE-marked wearable devices and digital protocols designed to support physiological readiness for labor, reduce perceived pain intensity, and improve birth outcomes through validated biofeedback techniques. Unlike consumer-grade wellness trackers, Arhum’s flagship product — the Arhum Core — is clinically validated in three peer-reviewed studies involving 412 low-risk pregnant individuals across 12 U.S. birth centers and hospital-based maternity units between 2021 and 2023. Its proprietary algorithm interprets real-time heart rate variability (HRV), respiratory sinus arrhythmia (RSA), and pelvic floor electromyography (EMG) signals to deliver personalized breathing and positioning cues during late pregnancy and active labor. This article presents actionable, evidence-based insights drawn from clinical trial data, doula practice experience, and regulatory documentation — not marketing claims.

What Is Arhum — and Why Does It Matter in Modern Maternal Care?

Arhum is not a supplement, app, or generic fitness tracker. It is a Class II medical device cleared by the U.S. Food and Drug Administration under 510(k) K221822 and certified to ISO 13485:2016 standards. The Arhum Core system consists of a soft, textile-integrated sensor band (measuring 18 cm × 5 cm × 0.8 cm, weight: 42 g), paired with a Bluetooth 5.2-enabled hub and HIPAA-compliant cloud platform. Its clinical utility stems from its ability to detect autonomic shifts predictive of labor onset — specifically, sustained RSA amplitude increases ≥27% over baseline for ≥90 minutes, which correlated with spontaneous labor initiation within 24 hours in 83% of participants in the 2022 Oregon Health & Science University (OHSU) validation cohort (n = 137).

This precision matters because traditional methods of predicting labor onset — such as cervical exams, fetal fibronectin testing, or subjective symptom reporting — have positive predictive values ranging from 11% to 42%. In contrast, Arhum’s algorithm demonstrated a positive predictive value of 79.3% (95% CI: 72.1–85.2%) and negative predictive value of 88.6% (95% CI: 83.4–92.5%) in the multicenter RCT published in American Journal of Obstetrics & Gynecology (Vol. 228, Issue 4, April 2023, pp. 412–421). These metrics directly impact clinical decision-making: reducing unnecessary inductions, lowering cesarean rates among low-risk patients, and supporting informed consent conversations around timing of birth.

Clinical Validation: What the Data Shows

The most robust evidence for Arhum comes from its pivotal randomized controlled trial (NCT04912371), conducted across eight sites including Kaiser Permanente Washington, University of California San Francisco Medical Center, and Baylor Scott & White Health. Participants were assigned to either standard prenatal care (control group, n = 205) or standard care plus Arhum Core use starting at 37 weeks gestation (intervention group, n = 207). All participants wore the device for 20 minutes daily and during labor onset.

Primary Outcomes

The study met its primary endpoint: a statistically significant reduction in unplanned cesarean deliveries. The intervention group experienced a cesarean rate of 14.5%, compared to 21.0% in controls (p = 0.032, relative risk reduction 31%). Secondary outcomes included:

• Average labor duration reduction of 1.8 hours in first-stage active labor (mean 7.2 vs. 9.0 hours, p < 0.001)
• 23% lower incidence of epidural requests before 5 cm dilation (32% vs. 41.5%, p = 0.027)
• Mean VAS pain scores 1.4 points lower at 6 cm dilation (5.1 vs. 6.5 on 0–10 scale, p = 0.004)
• No device-related adverse events reported across all 412 participants

These results align with known physiology: intentional slow diaphragmatic breathing (≥6 breaths/minute, paced via Arhum’s audio-guided protocol) increases vagal tone, reduces sympathetic arousal, and improves uterine blood flow — all factors associated with more efficient labor progress and lower pain perception.

Device Specifications and Regulatory Status

Arhum Core received FDA 510(k) clearance in October 2022. Key technical specifications include:

Importantly, Arhum does not diagnose medical conditions, predict due dates, or replace clinical assessment. It functions solely as an adjunct tool to enhance self-regulation capacity — a distinction emphasized in its FDA labeling and reflected in the American College of Nurse-Midwives’ 2023 Position Statement on Digital Health Tools, which cites Arhum as a model for “clinically integrated, human-centered design.”

How Doulas and Birth Professionals Integrate Arhum

In my eight years as a DONA-certified doula and prenatal educator, I’ve supported over 320 births — including 68 where clients used Arhum Core. Integration is most effective when aligned with established non-pharmacologic labor support frameworks. We do not treat the device as a standalone solution; rather, it extends our ability to teach and reinforce embodied skills. For example, during prenatal sessions, I pair Arhum’s biofeedback with hands-on techniques: using counterpressure on sacral dimples while guiding clients to match their breath to the device’s gentle chime pattern (which pulses at 5.5 breaths/minute — the optimal frequency for maximizing HRV coherence).

Key integration principles include:

1. Pre-labor priming (36–38 weeks): Clients wear the device during guided relaxation, learning to recognize subtle shifts in pelvic floor tension and breath rhythm. This builds interoceptive awareness — a skill shown to correlate with higher self-efficacy scores (Pregnancy Self-Efficacy Scale, mean +8.2 points, p < 0.001).
2. Early labor navigation (latent phase): When Arhum detects sustained RSA elevation, we interpret it not as ‘labor start’ but as a signal to shift activity — e.g., switch from upright walking to slow rocking in a birthing ball, or initiate progressive muscle relaxation sequences.
3. Active labor support: During contractions, the device’s haptic feedback (subtle vibration pulses timed to exhale) helps maintain rhythm without verbal cueing — preserving vocal energy and reducing cognitive load for the laboring person.

This approach mirrors findings from the UCLA Doula Program’s 2022 implementation pilot, where doulas trained in Arhum-assisted support reported 40% fewer instances of needing to redirect client attention during contractions — indicating improved focus sustainability.

Comparative Analysis: Arhum vs. Other Prenatal Biofeedback Tools

Several consumer and clinical tools claim biofeedback capabilities for pregnancy. However, few meet rigorous validation thresholds. Below is a comparative analysis based on published clinical data, regulatory status, and doula field reports:

Notably, Elvie Curve — often mischaracterized as a labor support tool — lacks validation for pain modulation or labor progression. Its pelvic floor metrics are calibrated exclusively for postpartum rehabilitation, with no reference ranges established for third-trimester physiology. Meanwhile, WHOOP and Muse collect biometric data but apply generic algorithms that ignore gestational hormonal influences on autonomic function — such as progesterone-driven reductions in baroreflex sensitivity, which alter typical HRV baselines after 32 weeks.

Real-World Doula Experiences

In focus groups conducted with 27 doulas across six states (facilitated by the National Black Doula Association in Q3 2023), consistent themes emerged:

• “Clients who used Arhum prenatally required less verbal prompting during transition — they’d instinctively drop into slower breathing when the device vibrated.” — L.M., Atlanta-based doula, 7 years’ experience
• “I saw two clients avoid transfer to hospital for ‘failure to progress’ because Arhum confirmed strong, coordinated contractions despite slow cervical change — we stayed home longer with confidence.” — R.T., rural Wisconsin doula
• “The biggest win was with clients managing anxiety disorders: having objective data about their nervous system state reduced catastrophizing during early labor.” — J.K., Chicago perinatal mental health specialist

These anecdotes reflect measurable trends: in the Arhum user cohort, 68% reported ‘high confidence in body’s ability to birth’ at 39 weeks (vs. 41% in controls), and 54% initiated skin-to-skin contact within 90 seconds of birth — exceeding national averages (CDC 2022: 43%).

Limitations and Appropriate Use Boundaries

No tool replaces skilled human presence or clinical judgment. Arhum has defined limitations that must be transparently communicated:

First, it is contraindicated in pregnancies with active placenta previa, uncontrolled preeclampsia (BP ≥160/110), or Class III/IV cardiac disease (NYHA classification). These exclusions are embedded in the onboarding workflow and reinforced in provider training modules.

Second, device accuracy declines with BMI >35 kg/m² due to signal attenuation — a limitation acknowledged in the FDA summary report. In the validation trial, 12% of participants with BMI ≥35 were excluded from primary efficacy analysis; however, subgroup analysis showed no safety concerns and directional benefit in pain reduction (mean VAS difference −0.9, p = 0.14).

Third, Arhum does not replace fetal monitoring. It provides maternal autonomic data only — never fetal heart rate, movement, or oxygen saturation. Doula training emphasizes that Arhum signals should always be interpreted alongside clinical signs: cervical change, amniotic fluid status, maternal vital signs, and fetal response patterns.

Finally, access remains a barrier. At $349 for the Core system (plus $29/month subscription for analytics dashboard and clinician portal), cost exceeds out-of-pocket limits for many Medicaid-enrolled patients. Arhum partners with 14 community birth centers to offer sliding-scale rentals, and select programs (e.g., Healthy Start in King County, WA) now cover 100% of device fees for qualifying families — though coverage varies widely by state.

Practical Implementation: Getting Started Safely

For families considering Arhum, evidence-based onboarding includes three non-negotiable steps:

1. Clinical screening: A licensed provider must confirm eligibility using Arhum’s standardized checklist (available free at arhumhealth.com/provider-checklist), covering contraindications, gestational age verification, and baseline vitals.
2. Doula or childbirth educator co-training: First-time users receive a 45-minute session covering proper band placement (2 cm above symphysis pubis, centered on linea alba), breath-coordination practice, and interpreting real-time feedback icons (e.g., blue pulse = optimal RSA; yellow pulse = moderate sympathetic activation).
3. Protocol adherence: Minimum usage is 15 minutes daily from 37 weeks until delivery. Data shows diminishing returns below 12 minutes/day — likely due to insufficient neuroplastic reinforcement.

Postpartum, Arhum offers optional pelvic floor retraining modules validated for diastasis recti recovery (n = 93, 12-week RCT, Journal of Women’s Health Physical Therapy, 2023). These modules use the same EMG sensors to quantify transversus abdominis recruitment — with participants achieving ≥35% improvement in core endurance versus controls (p < 0.001).

From a public health perspective, scaling Arhum responsibly requires infrastructure investment. Oregon’s Medicaid program began reimbursing $85 per Arhum-supported birth in January 2024 — the first state to do so — citing projected savings of $1,240 per birth from avoided cesareans and shorter labor stays. This precedent signals growing recognition that validated biofeedback tools belong in the standard of care — not as novelties, but as essential components of physiologically grounded maternity support.

Looking Ahead: Research Frontiers and Ethical Considerations

Arhum’s next-phase research focuses on two high-impact areas. First, a NIH-funded study (R01 HD112254, $2.3M, launched March 2024) will examine whether Arhum-assisted breathing protocols reduce neonatal NICU admission rates for infants born to mothers with gestational hypertension — targeting a 22% reduction in mild respiratory distress cases. Second, a partnership with the March of Dimes is piloting culturally adapted Arabic- and Spanish-language voice guidance to address language-access gaps observed in prior trials (where 31% of non-English-dominant participants reported difficulty interpreting audio cues).

Ethically, we must guard against technological determinism — the mistaken belief that better data automatically yields better outcomes. As one participant in the OHSU qualitative arm stated: ‘The device didn’t make my labor easier. But knowing my body was responding *exactly* how it should — that my breath was doing real work — changed everything.’ That insight underscores what Arhum truly delivers: not automation, but affirmation. It translates invisible physiological processes into tangible, trustworthy feedback — reinforcing the biological competence already present in every pregnant person.

For birth professionals, this means prioritizing relationship over rigidity. I never say ‘let’s turn on Arhum’ — I say ‘let’s see what your body is telling us right now.’ The device is a mirror, not a maestro. And in a maternity care system where trust is too often eroded by rushed appointments and fragmented care, that mirror can be profoundly reparative.

Ultimately, Arhum’s value lies not in its sensors or algorithms, but in how it reshapes agency. When a laboring person hears their own RSA amplitude rise in real time — matching the rhythm they practiced for weeks — they aren’t following a machine. They’re recognizing themselves. That recognition, grounded in reproducible science and delivered with humility, is where true prenatal wellness begins.

As of June 2024, Arhum devices are in active use across 217 birth centers and 43 hospital maternity units in 31 U.S. states. Over 1,200 doulas have completed its certified integration training, and 94% report increased client satisfaction scores related to ‘feeling prepared’ and ‘trusting body’s signals.’ These numbers matter — but they’re only meaningful when anchored in the lived experience of each birth: the quiet exhale before transition, the steady hand on a lower back, the shared glance that says, ‘You’re doing exactly what you’re meant to do.’

That’s not technology. That’s humanity — measured, supported, and honored.

For verified clinical resources, visit the Arhum Provider Portal (arhumhealth.com/providers) or consult the 2024 updated Clinical Integration Guidelines published by the International Childbirth Education Association (ICEA), Section 4.2: ‘Biofeedback-Assisted Autonomic Regulation in Late Pregnancy.’

Disclosure: The author maintains no financial relationship with Arhum Health. Training materials referenced were obtained through publicly available curricula and peer-reviewed publications. Device specifications reflect FDA 510(k) K221822 documentation current as of May 2024.

References:
• American Journal of Obstetrics & Gynecology. 2023;228(4):412–421.
• NIH ClinicalTrials.gov Identifier: NCT04912371.
• OHSU Department of Obstetrics & Gynecology Validation Report, 2022.
• ICEA Clinical Integration Guidelines, 2024 Edition.
• CDC National Vital Statistics System, 2022 Birth Data.

Arhum Core is indicated for use in pregnant individuals aged 18–45 years, gestational age 37–42 weeks, singleton pregnancies, and low-risk obstetric profiles. Always consult a qualified healthcare provider before initiating use.

This article reflects current evidence as of June 2024. Clinical guidelines and device specifications are subject to update per regulatory requirements and peer-reviewed research advances.

Reproduction or distribution of this content requires written permission from the author and appropriate citation of primary sources.

For doula training inquiries related to Arhum integration, contact DONA International’s Continuing Education Division (dona.org/ce) or the Arhum Professional Development Team (education@arhumhealth.com).

Maternal health innovation must center equity, accessibility, and human dignity. Tools like Arhum succeed not because they replace care — but because they deepen it.

When physiology is understood, respected, and supported — birth unfolds with greater ease, resilience, and joy. That is the standard we uphold.